Adam Veness SEC Filing Summary

Adam Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, Inc., reported a series of transactions on June 17, 2026. Veness acquired 30,000 shares of Common Stock through the exercise of a stock option, with the shares vesting over four years starting January 1, 2024. The exercise price was effectively $0, and the underlying security was also Common Stock. Following this acquisition, Veness disposed of all 30,000 shares. Additionally, Veness sold 16,771 shares at a weighted average price of $80.34 and another 13,229 shares at a weighted average price of $81.38. These transactions were executed under a Rule 10b5-1 trading plan. Post-transaction, Veness holds 0 shares of Common Stock directly. The weighted average prices reflect sales in ranges of $80.00-$80.99 and $81.00-$81.80, respectively. The option to buy the shares expires on January 23, 2034.